According to Zhitong Finance App News, Yingtai Medical (01501.HK) announced that in connection with the acquisition of the target company's total issued share capital of about 23.18% and 0.79%, respectively, the company and its designated wholly-owned subsidiary (that is, the transferee) entered into partnership rights transfer agreements with several existing partners (i.e. transferors) in Shanghai on July 23, 2026. Based on this, the transferee has agreed to receive 100% of Shanghai's partnership interests domestically, with a total consideration of about US$55.1202 million. Shanghai Yuanyi indirectly holds 579,866 Series B preferred shares of the target company, accounting for about 3.85% of the total issued share capital of the target company.

According to Zhitong Finance App News, Yingtai Medical (01501.HK) announced that in connection with the acquisition of the target company's total issued share capital of about 23.18% and 0.79%, respectively, the company and its designated wholly-owned subsidiary (that is, the transferee) entered into partnership rights transfer agreements with several existing partners (i.e. transferors) in Shanghai on July 23, 2026. Based on this, the transferee has agreed to receive 100% of Shanghai's partnership interests domestically, with a total consideration of about US$55.1202 million. Shanghai Yuanyi indirectly holds 579,866 Series B preferred shares of the target company, accounting for about 3.85% of the total issued share capital of the target company.